Viyash Scientific Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹268.65
Market cap
11,666 Cr
Stock P/E
76.7
P/B
3.75
Dividend yield
0.0%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 333 Cr | 346 Cr | 329 Cr | 361 Cr | 390 Cr | 369 Cr | 391 Cr | 402 Cr | 441 Cr | 424 Cr | 858 Cr | 920 Cr |
| Operating expenses (approx.) | 365 Cr | 323 Cr | 304 Cr | 330 Cr | 348 Cr | 334 Cr | 351 Cr | 354 Cr | 390 Cr | 370 Cr | 724 Cr | 720 Cr |
| EBITDA | -32 Cr | 23 Cr | 25 Cr | 32 Cr | 42 Cr | 35 Cr | 40 Cr | 48 Cr | 51 Cr | 54 Cr | 134 Cr | 200 Cr |
| OPM % | -9.5% | 6.7% | 7.6% | 8.7% | 10.8% | 9.4% | 10.2% | 11.8% | 11.5% | 12.7% | 15.7% | 21.8% |
| Other income | 0.79 Cr | 2 Cr | 5 Cr | 4 Cr | 3 Cr | 5 Cr | 6 Cr | 2 Cr | 4 Cr | 2 Cr | 14 Cr | 16 Cr |
| Interest | 10 Cr | 13 Cr | 13 Cr | 12 Cr | 16 Cr | 14 Cr | 15 Cr | 15 Cr | 14 Cr | 14 Cr | 17 Cr | 15 Cr |
| Depreciation | 14 Cr | 15 Cr | 15 Cr | 16 Cr | 16 Cr | 17 Cr | 17 Cr | 16 Cr | 15 Cr | 15 Cr | 59 Cr | 60 Cr |
| Profit before tax | -56 Cr | -3 Cr | 1 Cr | 3 Cr | 12 Cr | 8 Cr | 8 Cr | 16 Cr | 26 Cr | 27 Cr | 73 Cr | 125 Cr |
| Tax % | 37.7% | -122.4% | -616.0% | 51.7% | 24.5% | 19.7% | 20.0% | 36.4% | 31.2% | 27.8% | 33.6% | 47.0% |
| Net profit | -35 Cr | -7 Cr | 11 Cr | 1 Cr | 9 Cr | 6 Cr | 6 Cr | 10 Cr | 18 Cr | 20 Cr | 49 Cr | 66 Cr |
| EPS (₹) | ₹-1.40 | ₹-0.34 | ₹0.33 | ₹-0.04 | ₹0.26 | ₹0.10 | ₹0.14 | ₹0.37 | ₹0.57 | ₹0.59 | ₹0.89 | ₹1.20 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,039 Cr | 1,179 Cr | 1,362 Cr | 1,413 Cr | 1,421 Cr | 1,370 Cr | 1,551 Cr | 3,420 Cr | Sign in for TTM |
| Operating expenses (approx.) | 906 Cr | 999 Cr | 1,150 Cr | 1,293 Cr | 1,474 Cr | 1,326 Cr | 1,380 Cr | 2,768 Cr | Sign in for TTM |
| EBITDA | 134 Cr | 180 Cr | 212 Cr | 120 Cr | -53 Cr | 44 Cr | 172 Cr | 652 Cr | Sign in for TTM |
| OPM % | 12.9% | 15.3% | 15.5% | 8.5% | -3.7% | 3.2% | 11.1% | 19.1% | Sign in for TTM |
| Other income | 9 Cr | 10 Cr | 8 Cr | 11 Cr | 6 Cr | 11 Cr | 15 Cr | 44 Cr | Sign in for TTM |
| Interest | 33 Cr | 36 Cr | 24 Cr | 16 Cr | 36 Cr | 48 Cr | 61 Cr | 69 Cr | Sign in for TTM |
| Depreciation | 42 Cr | 51 Cr | 51 Cr | 51 Cr | 56 Cr | 62 Cr | 66 Cr | 234 Cr | Sign in for TTM |
| Profit before tax | 59 Cr | 94 Cr | 137 Cr | 53 Cr | -138 Cr | -55 Cr | 44 Cr | 349 Cr | Sign in for TTM |
| Tax % | 3.4% | 12.8% | 23.6% | 15.6% | 11.4% | 45.8% | 27.2% | 35.6% | Sign in for TTM |
| Net profit | 57 Cr | 82 Cr | 104 Cr | 45 Cr | -122 Cr | -30 Cr | 32 Cr | 225 Cr | Sign in for TTM |
| EPS (₹) | ₹2.00 | ₹2.87 | ₹3.87 | ₹1.67 | ₹-4.88 | ₹-1.44 | ₹0.88 | ₹4.09 | Sign in for TTM |
| Dividend payout % | — | — | — | 27.4% | — | — | 5.7% | 2.2% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 49 Cr | 50 Cr | 50 Cr | 50 Cr | 50 Cr | 50 Cr | 50 Cr | 87 Cr |
| Reserves | 0.0000 Cr | 693 Cr | 678 Cr | 643 Cr | 649 Cr | 607 Cr | 654 Cr | 2,824 Cr |
| Borrowings | — | — | — | — | 398 Cr | 451 Cr | 173 Cr | 134 Cr |
| Other liabilities | — | — | — | — | 382 Cr | 376 Cr | 659 Cr | 1,380 Cr |
| Total liabilities | — | — | — | — | 1,529 Cr | 1,540 Cr | 1,602 Cr | 4,628 Cr |
| Fixed assets (net) | — | — | — | — | 301 Cr | 249 Cr | 232 Cr | 1,138 Cr |
| CWIP | — | — | — | — | 51 Cr | 11 Cr | 15 Cr | 69 Cr |
| Investments | — | — | — | — | 0.05 Cr | 4 Cr | 0.08 Cr | 0.07 Cr |
| Other assets | — | — | — | — | 780 Cr | 811 Cr | 873 Cr | 2,255 Cr |
| Total assets | — | — | — | — | 1,529 Cr | 1,540 Cr | 1,602 Cr | 4,628 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 31 Cr | 17 Cr | 31 Cr | 83 Cr | 323 Cr |
| Cash from investing | — | — | — | -94 Cr | -65 Cr | -6 Cr | -25 Cr | -84 Cr |
| Cash from financing | — | — | — | 67 Cr | 32 Cr | -1 Cr | -61 Cr | -123 Cr |
| Net cash flow | — | — | — | 4 Cr | -16 Cr | 23 Cr | -2 Cr | 115 Cr |
| Free cash flow (OCF − Capex) | — | — | — | -2 Cr | -69 Cr | -0.21 Cr | 44 Cr | 188 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 185.7% | 17.5% | 22.1% | 10.0% | -9.5% | -1.5% | 11.1% | 12.9% |
| ROE % | 0.0% | 9.4% | 13.1% | 6.0% | -16.2% | -5.0% | 2.8% | 5.7% |
| Debtor days | — | — | — | — | 87 | 89 | — | — |
| Inventory days | — | — | — | — | 182 | 206 | 227 | 212 |
| Days payable | — | — | — | — | 128 | 155 | — | — |
| Cash conversion cycle | — | — | — | — | 141 | 141 | 227 | 212 |
| Debt / equity | — | — | — | — | 0.57 | 0.69 | 0.22 | 0.04 |
| Current ratio | — | — | — | — | 1.48 | 1.29 | 1.73 | 2.38 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | — | 8.78 | 0.64 | -0.19 |
Compare with peers
Loading peers…